Literature DB >> 21411537

Vaccination alters the balance between protective immunity, exhaustion, escape, and death in chronic infections.

Philip L F Johnson1, Beth F Kochin, Megan S McAfee, Ingunn M Stromnes, Roland R Regoes, Rafi Ahmed, Joseph N Blattman, Rustom Antia.   

Abstract

While T cell-based vaccines have the potential to provide protection against chronic virus infections, they also have the potential to generate immunopathology following subsequent virus infection. We develop a mathematical model to investigate the conditions under which T cells lead to protection versus adverse pathology. The model illustrates how the balance between virus clearance and immune exhaustion may be disrupted when vaccination generates intermediate numbers of specific CD8 T cells. Surprisingly, our model suggests that this adverse effect of vaccination is largely unaffected by the generation of mutant viruses that evade T cell recognition and cannot be avoided by simply increasing the quality (affinity) or diversity of the T cell response. These findings should be taken into account when developing vaccines against persistent infections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21411537      PMCID: PMC3094965          DOI: 10.1128/JVI.00166-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Viral infection results in massive CD8+ T cell expansion and mortality in vaccinated perforin-deficient mice.

Authors:  Vladimir P Badovinac; Sara E Hamilton; John T Harty
Journal:  Immunity       Date:  2003-04       Impact factor: 31.745

2.  Uses and abuses of mathematics in biology.

Authors:  Robert M May
Journal:  Science       Date:  2004-02-06       Impact factor: 47.728

Review 3.  Memory CD8 T-cell differentiation during viral infection.

Authors:  E John Wherry; Rafi Ahmed
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

4.  Vaccination for disease.

Authors:  S Oehen; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1991-01-11       Impact factor: 47.728

5.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

6.  An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.

Authors:  A Z Kapikian; R H Mitchell; R M Chanock; R A Shvedoff; C E Stewart
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

7.  Antibody-enhanced dengue virus infection in primate leukocytes.

Authors:  S B Halstead; E J O'Rourke
Journal:  Nature       Date:  1977-02-24       Impact factor: 49.962

8.  Estimating the precursor frequency of naive antigen-specific CD8 T cells.

Authors:  Joseph N Blattman; Rustom Antia; David J D Sourdive; Xiaochi Wang; Susan M Kaech; Kaja Murali-Krishna; John D Altman; Rafi Ahmed
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

9.  Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.

Authors:  V A Fulginiti; J J Eller; O F Sieber; J W Joyner; M Minamitani; G Meiklejohn
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

10.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

Authors:  M Juliana McElrath; Stephen C De Rosa; Zoe Moodie; Sheri Dubey; Lisa Kierstead; Holly Janes; Olivier D Defawe; Donald K Carter; John Hural; Rama Akondy; Susan P Buchbinder; Michael N Robertson; Devan V Mehrotra; Steven G Self; Lawrence Corey; John W Shiver; Danilo R Casimiro
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

View more
  22 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

2.  Post-treatment control of HIV infection.

Authors:  Jessica M Conway; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

3.  A review of computational and mathematical modeling contributions to our understanding of Mycobacterium tuberculosis within-host infection and treatment.

Authors:  Denise Kirschner; Elsje Pienaar; Simeone Marino; Jennifer J Linderman
Journal:  Curr Opin Syst Biol       Date:  2017-05-22

4.  On the role of CD8 T cells in the control of persistent infections.

Authors:  Sean P Stromberg; Rustom Antia
Journal:  Biophys J       Date:  2012-10-16       Impact factor: 4.033

5.  How do antigenically varying pathogens avoid cross-reactive responses to invariant antigens?

Authors:  Philip L F Johnson; Beth F Kochin; Rafi Ahmed; Rustom Antia
Journal:  Proc Biol Sci       Date:  2012-03-21       Impact factor: 5.349

Review 6.  Solving Immunology?

Authors:  Yoram Vodovotz; Ashley Xia; Elizabeth L Read; Josep Bassaganya-Riera; David A Hafler; Eduardo Sontag; Jin Wang; John S Tsang; Judy D Day; Steven H Kleinstein; Atul J Butte; Matthew C Altman; Ross Hammond; Stuart C Sealfon
Journal:  Trends Immunol       Date:  2016-12-13       Impact factor: 16.687

7.  Vaccination by delayed treatment of infection.

Authors:  Sean P Stromberg; Rustom Antia
Journal:  Vaccine       Date:  2011-10-30       Impact factor: 3.641

Review 8.  Mathematical modeling of within-host Zika virus dynamics.

Authors:  Katharine Best; Alan S Perelson
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

9.  Early events in hepatitis B infection: the role of inoculum dose.

Authors:  Stanca M Ciupe; Naveen K Vaidya; Jonathan E Forde
Journal:  Proc Biol Sci       Date:  2021-02-10       Impact factor: 5.349

Review 10.  Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.

Authors:  Stephan Olschläger; Lukas Flatz
Journal:  PLoS Pathog       Date:  2013-04-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.